Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

NCT02175004 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

FAP
Familial Amyloid Polyneuropathy
TTR
Transthyretin
Amyloidosis

Interventions

DRUG: Inotersen

Sponsor

Ionis Pharmaceuticals, Inc.